Welcome to our dedicated page for Inspira Technologies Oxy Bhn news (Ticker: IINN), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy Bhn stock.
Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) generates news across respiratory support, blood monitoring, and emerging diagnostics, reflecting its role as a commercial-stage medical device company. Company announcements highlight the FDA-cleared INSPIRA ART100 cardiopulmonary support system, the development of the INSPIRA ART500 oxygenation platform, and progress with the HYLA non-invasive blood sensor, including completion of a clinical study and preparation for regulatory submission.
News coverage also follows Inspira’s strategic move into liquid biopsy diagnostics. The company has outlined a non-binding term sheet and proposed transaction to acquire an advanced liquid biopsy platform focused initially on breast cancer and circulating tumor cell analysis, alongside a concurrent equity investment and a contingent value rights framework for existing shareholders. These updates provide insight into how Inspira aims to extend its expertise in blood-based technologies into oncology diagnostics.
Investors and observers can expect IINN news to include regulatory milestones, such as submissions and anticipated approvals in markets like the United Arab Emirates, as well as updates on binding purchase orders, deployment timelines, and collaborations. Recent items have covered a registered direct offering, a Standby Equity Purchase Agreement, expansion of laboratory infrastructure, and an AI-based training alliance with Bites Learning Ltd. Leadership appointments and shareholder meeting notices also appear in the company’s news flow.
This news page aggregates these developments in one place, helping readers follow Inspira’s clinical, regulatory, commercial, and corporate updates over time.
Inspira Technologies (NASDAQ: IINN) completed the clinical study for its HYLA non-invasive blood sensor on Nov. 13, 2025 and is progressing toward regulatory submission.
Company-reported results and ongoing lab tests show 95%–99% accuracy across measured parameters. Inspira said it will enter final validation and verification before submitting for approval and is integrating machine-learning to expand HYLA’s physiological parameter set beyond current non-invasive monitoring capabilities.
Inspira Technologies (NASDAQ: IINN) completed its regulatory submission of the FDA-cleared ART100 system to the United Arab Emirates Ministry of Health and Prevention (MOHAP) on Nov 6, 2025, and expects final approval within days.
The company said this milestone follows high-level UAE government discussions and positions ART100 for potential nationwide deployment and clinical integration across Gulf-region enterprise healthcare networks, advancing Inspira's global commercialization roadmap.
Inspira (NASDAQ:IINN) announced on October 22, 2025 a strategic collaboration with Bites Learning to embed Bites’ AI-powered training and guidance platform across Inspira’s global ecosystem. The integration will be built into future versions of the INSPIRA ART100 cardiopulmonary support system and the HYLA real-time blood sensor to standardize onboarding, accelerate training, and reduce support burdens for hospitals, distributors, and users.
Key features include adaptive AI training modules, personalized on-demand knowledge feeds, analytics for training adoption and audit-readiness, a built-in commercial value layer, joint marketing, and provisions to evaluate deeper commercial or strategic transactions.
Inspira Technologies (NASDAQ: IINN) announced two leadership changes on October 21, 2025: the appointment of Mike Hershkovitz as Vice President of Global Sales and the appointment of Sivan Matza as an independent member of the company’s board of directors. Ms. Matza will join the compensation, audit and financial statement examination committees and succeeds Limor Rosen, who is stepping down. Mr. Hershkovitz, based in the United States, brings nearly two decades of commercial experience including senior roles at Johnson & Johnson and will lead global sales and hospital adoption efforts. The company highlighted these additions as strategic to support governance and global commercialization as Inspira advances its diagnostic and life-support technologies.
Inspira (NASDAQ: IINN) announced two leadership appointments on October 21, 2025: Mike Hershkovitz as Vice President of Global Sales and Sivan Matza as an independent member of the board of directors. Ms. Matza will join the compensation, audit and financial statement examination committees and succeeds Limor Rosen, who is stepping down.
Ms. Matza oversees tens of billions of dollars in assets at a leading international investment firm and brings experience in global finance, regulation and accounting. Mr. Hershkovitz brings nearly two decades of commercial leadership, including senior roles at Johnson & Johnson, to lead Inspira’s sales strategy and hospital adoption initiatives worldwide.
Inspira Technologies (NASDAQ:IINN) reported significant achievements for H1 2025, highlighted by $49.5 million in binding purchase orders for its ART100 system. The company generated its first commercial revenue of $289,000 with initial product sales.
Key developments include successful human treatment validation at Westchester Medical Center, 97.35% accuracy for the HYLA blood sensor, and strategic patent protection until 2043. The company targets a $70 million annual revenue run rate by 2026.
Financial results show increased operating expenses to $7.2 million, up from $5.8 million in H1 2024, with a net loss of $6.4 million. Cash position stood at $2.1 million as of June 30, 2025, with an additional $4.7 million raised through ATM offerings by October 2025.
Inspira Technologies (NASDAQ: IINN) announced the upcoming debut of its HYLA blood sensor at the U.S. ELSO Annual Conference in Washington, D.C., from September 27-30, 2025. The sensor has demonstrated 97.35% accuracy compared to standard blood gas analyzers.
During the conference, management will conduct meetings with key decision-makers from global medical device companies and hospital networks to discuss commercialization and strategic partnerships. The company will also showcase its FDA-cleared ART100 system, demonstrating its comprehensive platform of life-support and monitoring solutions.
Inspira Technologies (NASDAQ: IINN) announced breakthrough performance results for its HYLA™ blood sensor, achieving 97.35% accuracy in its latest testing phase ahead of FDA submission. The HYLA sensor provides continuous, non-invasive blood monitoring through optical measurement technology.
The device offers second-by-second monitoring capabilities and is compatible with various medical procedures including cardiopulmonary bypass and dialysis. Targeting the two-million annual open-heart surgery patients globally, HYLA is designed both as a standalone device and for integration with Inspira's ART device line, implementing a razor-and-blade revenue model.
Inspira Technologies (NASDAQ: IINN) announced that a top U.S. Honor Roll hospital has expanded the use of its INSPIRA™ ART100 system to include lung transplantation procedures. The hospital, ranked among the nation's top 20 by U.S. News & World Report 2025-2026, made this decision following positive experience with the system in previous clinical applications.
This expansion into lung transplantation, one of the most demanding respiratory care applications, represents significant validation of the ART100 system's performance and clinical value. The development follows Inspira's recent securing of multi-million dollar binding government orders for ART100 systems, highlighting the company's growing commercial presence.
Inspira Technologies (NASDAQ: IINN) has secured a crucial U.S. patent for its ART500 core technology, featuring low flow rates extracorporeal oxygenation system. The patent, which includes 16 novel claims and extends protection until 2043, positions Inspira to target an estimated $20 billion market for advanced respiratory support.
The ART500 system represents a breakthrough in respiratory care, designed for conscious, spontaneously breathing patients who need support but may not require traditional high-flow ECMO systems. This innovation creates a new therapeutic category, bridging a significant gap in current treatment options.